Equities Analysts Set Expectations for ZNTL FY2026 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) – HC Wainwright boosted their FY2026 EPS estimates for shares of Zentalis Pharmaceuticals in a report issued on Tuesday, November 10th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($1.85) for the year, up from their previous forecast of ($2.39). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($2.15) per share. HC Wainwright also issued estimates for Zentalis Pharmaceuticals’ Q4 2026 earnings at ($0.44) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.49) EPS, Q4 2027 earnings at ($0.50) EPS, FY2027 earnings at ($1.90) EPS, FY2028 earnings at ($1.64) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at ($0.42) EPS.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Monday, November 9th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.20.

ZNTL has been the topic of several other reports. Mizuho started coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Friday, October 2nd. William Blair began coverage on shares of Zentalis Pharmaceuticals in a report on Wednesday, September 16th. They issued an “outperform” rating for the company. Jefferies Financial Group upgraded shares of Zentalis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 14th. Finally, Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They set a “buy” rating and a $11.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.29.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $1.89 on Thursday. The company has a market capitalization of $135.46 million, a P/E ratio of -0.98 and a beta of 1.91. Zentalis Pharmaceuticals has a one year low of $1.28 and a one year high of $6.95. The stock has a 50-day moving average price of $2.62 and a 200 day moving average price of $3.39.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. 5AM Venture Management LLC bought a new stake in Zentalis Pharmaceuticals in the second quarter worth approximately $19,147,378. BlackRock Inc. bought a new position in shares of Zentalis Pharmaceuticals during the 2nd quarter valued at $18,205,000. Bank of America Corp DE acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $5,406,000. Primecap Management Co. CA acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at $4,643,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new stake in Zentalis Pharmaceuticals in the second quarter worth $3,676,000.

Insider Buying and Selling

In related news, major shareholder Group Walters purchased 4,335,000 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the transaction, the insider directly owned 17,844,973 shares of the company’s stock, valued at $62,457,405.50. This trade represents a 32.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.80% of the stock is currently owned by corporate insiders.

Latest Zentalis Pharmaceuticals News

These are some of the ZNTL news items that stood out recently:

• Positive Sentiment: Wedbush upgraded ZNTL from “Neutral” to “Outperform” and raised its price target to $6 from $5, signaling a more bullish view. Article: Zentalis Pharmaceuticals Stock Rating Upgraded by Wedbush
• Positive Sentiment: HC Wainwright raised its EPS estimates for 2026–2028, projecting smaller losses, including FY2027 EPS of ($1.90) versus its prior estimate of ($2.76), and maintained its “Buy” rating and $10 target. These improved forecasts are the main positive earnings signal, though the company is still expected to report losses. Zentalis Pharmaceuticals analyst estimates
• Neutral Sentiment: Morgan Stanley reiterated its “Hold” rating, indicating it has not turned more bullish alongside Wedbush. Article: Morgan Stanley Remains a Hold on Zentalis Pharmaceuticals

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company’s research is centered on therapies designed to target biological pathways involved in tumor growth, survival and resistance to existing treatments. Zentalis’ lead product candidate is azenosertib, formerly known as ZN-c3, an oral inhibitor of WEE1, a protein involved in regulating the cell cycle and DNA-damage response.